tetrathiomolybdate and Huntington-Disease

tetrathiomolybdate has been researched along with Huntington-Disease* in 2 studies

Reviews

1 review(s) available for tetrathiomolybdate and Huntington-Disease

ArticleYear
Molybdenum Metallopharmaceuticals Candidate Compounds - The "Renaissance" of Molybdenum Metallodrugs?
    Current medicinal chemistry, 2016, Volume: 23, Issue:29

    Metal-based drugs, also called "metallopharmaceuticals" or "metallodrugs", are examples of sophisticated compounds that have been used in inorganic medicinal chemistry as therapeutic agents for a long time. Few of them have shown substantially promising results and many of them have been used in different phases of clinical trials. The Mo-based metallodrugs were successfully applied in the past for treating conditions such as anemia or Wilson's disease. Moreover, Mo complexes are supposed to exert their effect by intercalation/ cleavage of DNA/RNA, arrest of the cell cycle, and alteration of cell membrane functions. However, in the current literature, there are no reliable and in-depth reviews about the hypothetical therapeutic applications of all of the known molybdenum complexes as metallopharmaceuticals/ metallodrugs. The main emphasis was on the in-depth review of the potential applications of Mo-based complexes in medicinal chemistry as metallopharmaceuticals in treating diseases such as cancer and tumors, Wilson's disease, diabetes mellitus, Huntington's disease, atherosclerosis, and anemia. It must be emphasized that today the development of innovative and new Mo-based metalo-pharmaceuticals is not rapid, and hence the aim of this paper was also to inspire colleagues working in the field of Mo compounds who are trying to find "signpost" for research. The authors hope that this article will increase interest and initiate the Renaissance of Mo-compounds among medicinal inorganic chemists. This paper is the first review article in the literature that refers to and emphasizes many different and complex aspects of possible applications and capabilities of Mo-based metallodrugs.

    Topics: Animals; Atherosclerosis; Cell Cycle Checkpoints; Coordination Complexes; Hepatolenticular Degeneration; Humans; Huntington Disease; Molybdenum; Tungsten Compounds

2016

Other Studies

1 other study(ies) available for tetrathiomolybdate and Huntington-Disease

ArticleYear
Evaluation of tetrathiomolybdate in the R6/2 model of Huntington disease.
    Neuroscience letters, 2009, Mar-06, Volume: 452, Issue:1

    Huntington disease is an uncommon autosomal dominant neurodegenerative disorder caused by expanded polyglutamine repeats in the huntingtin protein. The proximate mechanisms responsible for neurodegeneration are unknown. Copper ions may play a role in Huntington disease by promoting oligomerization of expanded polyglutamine repeat protein fragments. Ammonium tetrathiomolybdate is a copper complexing agent with demonstrated tolerability and efficacy in another neurodegenerative disorder, Wilson disease. We evaluated ammonium tetrathiomolybdate in the R6/2 transgenic mouse model of Huntington disease. Ammonium tetrathiomolybdate treatment delayed the onset of motor dysfunction in R6/2 mice. There was a trend towards reduced striatal degeneration, suggesting a neuroprotective effect of ammonium tetrathiomolybdate in this model. Given its known tolerability in humans with neurodegeneration, ammonium tetrathiomolybdate could be considered as a candidate for clinical trials in Huntington disease.

    Topics: Age Factors; Animals; Brain; Disease Models, Animal; Huntington Disease; Intranuclear Inclusion Bodies; Mice; Mice, Transgenic; Molybdenum; Motor Activity; Reaction Time; Survival Rate

2009